down arrow

Enzo Biochem, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2941001024
USD
0.70
0.01 (1.66%)

Aug 19

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.690.70

52 Week

0.251.19
Valuation
Technical
Day's Volume

CASH

361.75 k

Shareholding (Jan 2025)

FII

0.79%

Held by 14 FIIs

DII

91.68%

Held by 9 DIIs

Promoter

0.00%

How big is Enzo Biochem, Inc.?

22-Jun-2025

As of Jun 18, Enzo Biochem, Inc. has a market capitalization of 28.30 million, with net sales of 29.09 million and a net profit of -7.60 million over the last four quarters. The company's shareholder's funds are 56.11 million, and total assets are 85.76 million as of Jul 24.

Market Cap: <BR>As of Jun 18, Enzo Biochem, Inc. has a market capitalization of 28.30 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Enzo Biochem, Inc. reported net sales of 29.09 million and a net profit of -7.60 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Jul 24, the company's shareholder's funds amounted to 56.11 million, while total assets were reported at 85.76 million.

Read More

What does Enzo Biochem, Inc. do?

22-Jun-2025

Enzo Biochem, Inc. is a micro-cap bioscience company that develops products and services in the Pharmaceuticals & Biotechnology sector. As of January 2025, it reported net sales of $7 million and a net loss of $1 million, with a market cap of $28.30 million.

Overview: <BR>Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Million (Quarterly Results - Jan 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Jan 2025) <BR>Market-cap: USD 28.30 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 1,757.33% <BR>Debt Equity: -0.82 <BR>Return on Equity: -14.89% <BR>Price to Book: 0.65<BR><BR>Contact Details: <BR>Address: 60 EXECUTIVE BLVD, FARMINGDALE NY: 11735 <BR>Tel: 1 516 7555500 <BR>Website: http://www.enzo.com/

Read More

Who are in the management team of Enzo Biochem, Inc.?

22-Jun-2025

As of March 2022, the management team of Enzo Biochem, Inc. includes Dr. Elazar Rabbani as Chairman and CEO, with Mr. Dov Perlysky as Lead Independent Director and independent directors Dr. Rebecca Fischer, Dr. Mary Tagliaferri, and Dr. Ian Walters.

As of March 2022, the management team of Enzo Biochem, Inc. includes Dr. Elazar Rabbani, who serves as the Chairman of the Board, Chief Executive Officer, and Secretary. Additionally, the board features Mr. Dov Perlysky as the Lead Independent Director, along with independent directors Dr. Rebecca Fischer, Dr. Mary Tagliaferri, and Dr. Ian Walters.

Read More

Is Enzo Biochem, Inc. overvalued or undervalued?

20-Sep-2025

As of June 9, 2022, Enzo Biochem, Inc. is considered overvalued and risky due to its negative financial metrics, including a Price to Book Value of 0.67, an EV to EBITDA ratio of 1.12, and poor stock performance compared to the S&P 500, with a YTD return of -2.16% and a 5Y return of -70.39%.

As of 9 June 2022, the valuation grade for Enzo Biochem, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.67 and an EV to EBITDA ratio of 1.12, which suggests that the market may not be accurately pricing in the challenges faced by the company. Additionally, the negative ROE of -12.03% further underscores the financial difficulties.<BR><BR>In comparison to its peers, Enzo Biochem, Inc. has a significantly lower EV to EBITDA ratio than BioAtla, Inc. at -0.2934, highlighting its underperformance within the industry. Furthermore, the company's stock has underperformed against the S&P 500 over multiple periods, with a YTD return of -2.16% compared to the S&P 500's 12.22%, and a staggering 5Y return of -70.39% against the S&P's 96.61%. This trend reinforces the notion that Enzo Biochem, Inc. is currently overvalued.

Read More

Is Enzo Biochem, Inc. technically bullish or bearish?

20-Sep-2025

As of July 1, 2025, Enzo Biochem, Inc. is in a mildly bearish trend, indicated by mixed technical signals and significant underperformance against the S&P 500, with a 1-year return of -37.60% compared to the index's 17.14%.

As of 1 July 2025, the technical trend for Enzo Biochem, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The daily moving averages indicate a mildly bearish trend, while the weekly RSI is bearish. The MACD shows bullish momentum on the weekly but is mildly bullish on the monthly, suggesting mixed signals. The Bollinger Bands are bullish weekly but mildly bearish monthly, and the KST is bullish weekly but bearish monthly. <BR><BR>In terms of performance, Enzo Biochem has underperformed significantly against the S&P 500 over the longer term, with a 1-year return of -37.60% compared to the S&P 500's 17.14%, and a 5-year return of -70.39% versus 96.61% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

10,873.16%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

-14.89%

stock-summary
Price to Book

0.84

Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Apr 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.8%
0%
24.8%
6 Months
34.9%
0%
34.9%
1 Year
-37.6%
0%
-37.6%
2 Years
-56.32%
0%
-56.32%
3 Years
-73.73%
0%
-73.73%
4 Years
-78.09%
0%
-78.09%
5 Years
-70.39%
0%
-70.39%

Enzo Biochem, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Enzo Biochem, Inc. technically bullish or bearish?

As of 1 July 2025, the technical trend for Enzo Biochem, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The daily moving averages indicate a mildly bearish trend, while the weekly RSI is bearish. The MACD shows bullish momentum on the weekly but is mildly bullish on the monthly, suggesting mixed signals. The Bollinger Bands are bullish weekly but mildly bearish monthly, and the KST is bullish weekly but bearish monthly. In terms of performance, Enzo Biochem has underperformed significantly against the S&P 500 over the longer term, with a 1-year return of -37.60% compared to the S&P 500's 17.14%, and a 5-year return of -70.39% versus 96.61% for the index....

Read More

Is Enzo Biochem, Inc. overvalued or undervalued?

As of 9 June 2022, the valuation grade for Enzo Biochem, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.67 and an EV to EBITDA ratio of 1.12, which suggests that the market may not be accurately pricing in the challenges faced by the company. Additionally, the negative ROE of -12.03% further underscores the financial difficulties. In comparison to its peers, Enzo Biochem, Inc. has a significantly lower EV to EBITDA ratio than BioAtla, Inc. at -0.2934, highlighting its underperformance within the industry. Furthermore, the company's stock has underperformed against the S&P 500 over multiple periods, with a YTD return of -2.16% compared to the S&P 500's 12.22%, and a staggering 5Y return of -70.39% against the S&P's 96.61%. This trend reinforces the notion that Enz...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-19.28%
EBIT Growth (5y)
9.74%
EBIT to Interest (avg)
-12.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
1.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
36.14%
ROCE (avg)
0.33%
ROE (avg)
1.91%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
0.94
EV to EBITDA
1.12
EV to Capital Employed
-1.06
EV to Sales
-0.27
PEG Ratio
NA
Dividend Yield
1581.60%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-12.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jan 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (7.53%)

Foreign Institutions

Held by 14 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -12.33% vs 17.74% in Jan 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is -100.00% vs 61.29% in Jan 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.40",
          "val2": "7.30",
          "chgp": "-12.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.60",
          "val2": "-0.90",
          "chgp": "-188.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-1.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-456.70%",
          "val2": "-170.70%",
          "chgp": "-28.60%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 2.57% vs -4.60% in Jul 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is 60.80% vs -23.15% in Jul 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.90",
          "val2": "31.10",
          "chgp": "2.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.50",
          "val2": "-16.90",
          "chgp": "49.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.70",
          "val2": "-6.00",
          "chgp": "38.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-25.00",
          "chgp": "60.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-305.00%",
          "val2": "-629.10%",
          "chgp": "32.41%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQstock-summary
Apr'25
Jan'25
Change(%)
Net Sales
6.40
7.30
-12.33%
Operating Profit (PBDIT) excl Other Income
-2.60
-0.90
-188.89%
Interest
0.00
0.00
Exceptional Items
-0.50
-0.30
-66.67%
Consolidate Net Profit
-2.40
-1.20
-100.00%
Operating Profit Margin (Excl OI)
-456.70%
-170.70%
-28.60%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Apr 2025 is -12.33% vs 17.74% in Jan 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is -100.00% vs 61.29% in Jan 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jul'24stock-summary
Jul'24
Jul'23
Change(%)
Net Sales
31.90
31.10
2.57%
Operating Profit (PBDIT) excl Other Income
-8.50
-16.90
49.70%
Interest
0.20
0.00
Exceptional Items
-3.70
-6.00
38.33%
Consolidate Net Profit
-9.80
-25.00
60.80%
Operating Profit Margin (Excl OI)
-305.00%
-629.10%
32.41%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jul 2024 is 2.57% vs -4.60% in Jul 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jul 2024 is 60.80% vs -23.15% in Jul 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Enzo Biochem, Inc. stock-summary
stock-summary
Enzo Biochem, Inc.
Pharmaceuticals & Biotechnology
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
Company Coordinates stock-summary
Company Details
60 EXECUTIVE BLVD , FARMINGDALE NY : 11735
stock-summary
Tel: 1 516 7555500
stock-summary
http://www.enzo.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."